Tyrosine kinase mutations of JAK2 are rare events in AML but influence prognosis of patients with CBF-leukemias

Haematologica

Volumn 92, Issue 1, 2007, Pages 137-138

  Illmer, Thomas ^a   Schaich, Markus ^a   Ehninger, Gerhard ^a   Thiede, Christian ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

AML; CBF leukemias; JAK2

Indexed keywords

CORE BINDING FACTOR; JANUS KINASE 2; PROTEIN TYROSINE KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; GENE MUTATION; HUMAN; HUMAN CELL; KARYOTYPE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PROGNOSIS;

AGED; CELL TRANSFORMATION, NEOPLASTIC; CORE BINDING FACTORS; CYTOGENETICS; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; JANUS KINASE 2; LEUKEMIA; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKOCYTE COUNT; MIDDLE AGED; MUTATION; PROGNOSIS;

EID: 33846926552     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10489     Document Type: Article

References (9)

1. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout Cet al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
2. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.
3. Frohling S, Lipka DB, Kayser S, Scholl C, Schlenk RF, Dohner H, et al. Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. Blood 2006;107:1242-3.
4. Lee JW, Kim YG, Soung YH, Han KJ, Kim SY, Rhim HSet al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 2006;25:1434-6.
5. Ruchatz H, Coluccia AM, Stano P, Marchesi E, Gambacorti-Passerini C. Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells. Exp Hematol 2003;31:309-15.
6. Walz C, Crowley BJ, Hudon HE, Gramlich JL, Neuberg DS, Podar K, et al. Activated Jak2 with the V617F Point Mutation Promotes G1/S Phase Transition. J Biol Chem 2006;281:18177-83.
7. Schaich M, Ritter M, Illmer T, Lisske P, Thiede C, Schakel U, et al. Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia. Br J Haematol 2001;112:300-7.
8. Jones AV, Silver RT, Waghorn K, Curtis C, Kreil S, Zoi K, et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon α. Blood 2006;107:3339-41.
9. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99:4326-35.